Name: A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance (Video) | JoVE Journal
Uploaded: 2025-11-07T13:00:00.000+00:00
Duration: 5 min 19 s
Description: Learn super-active surveillance for low-risk prostate cancer using cryoablation and advanced imaging technologies. This method reduces overtreatment while preserving patient quality of life and functional outcomes.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This study was sponsored by the General Project Fund of the Civil Aviation General Hospital, No. 202214.

The study has been reviewed by the Ethics Committee of the Civil Aviation General Hospital. Ethical statement. Written, informed consent was obtained from the patients.
1. Set the following inclusion criteria
<ol>
	<li>Include patients following pathological confirmation of prostate adenocarcinoma through prostate system puncture.</li>
	<li>Include patients with PSA &#60; 10 ng/mL, Gleason score &#60; 7, and cT1N0M0 or T2aN0M0 stage (classified as low risk according to D&#39;Amico risk stratification).</li>
	<li>Include patients who refuse to undergo radical surgery, radiotherapy, or endocrine therapy.</li>
	<li>Include patients who refuse to accept AS or watchful waiting.</li>
</ol>
2. Exclusion criteria
<ol>
	<li>Exclude patients with a previous diagnosis of prostate cancer with prior radical surgery, radiotherapy, or endocrine therapy.</li>
	<li>Exclude patients with a history of mental illness, such as depression or severe anxiety, suspected or diagnosed alcohol or drug addiction.</li>
	<li>Exclude patients if they have diseases that can lead to systemic immune dysfunction.</li>
	<li>Exclude patients participating in other clinical trials.</li>
	<li>Exclude patients with surgical contraindications.</li>
</ol>
3. Instruments for operation
<ol>
	<li>Ensure the availability of a cryotherapy system and real-time image fusion ultrasound.</li>
	<li>Prepare a USB flash drive containing 18F-PSMA PET/MR imaging data.</li>
	<li>Choose the appropriate target framework for the puncture. Select different puncture targets based on prostate volume and tumor location. To ensure the precision of cryotherapy, perform 3D customization of puncture targets for some patients.</li>
	<li>Prepare a V-shaped variable probe (freezing adjustment range of the probe from 1.5 cm to 5 cm in diameter) and two temperature probes.</li>
</ol>
4. Preparation for operation
<ol>
	<li>Connect the USB flash drive to the integrated ultrasound system.</li>
	<li>Preoperatively Import the patients&#39; imaging data into ultrasound fusion software for 18F-PSMA PET/MR image target planning and marking (Figure 1).</li>
	<li>Complete the preoperative planning for cryoablation (Figure 2).</li>
</ol>
5. Procedure
<ol>
	<li>Position the patient in the lithotomy position and infuse Levofloxacin (0.5 g) 30 min before the start of surgery. After the import of Levofloxacin, retain a three-lumen pure silicone catheter.</li>
	<li>Apply ultrasound and preoperative planning markers in 18F-PSMA PET/MR imaging for intraoperative registration (Figure 3).</li>
	<li>Complete the targeted puncture of the cryoprobe (Figure 4).</li>
	<li>Insert the variable probe into the target lesion based on the image fusion results.</li>
	<li>Place two temperature probes in the perineal puncture, one located anterior to the rectum on the same side or in the Denonvilliers fascia and the other placed proximally adjacent to the neurovascular bundle on the same side.</li>
	<li>Use a 50 &#176;C constant-temperature saline solution to irrigate the bladder through the three-lumen urinary catheter to protect the urethra and prevent urethral frostbite.</li>
	<li>Start the cryotherapy system (Figure 5).
	<ol>
		<li>Rapidly lower the probe&#39;s front end to below -140 &#176;C.</li>
		<li>Use ultrasound for real-time monitoring of the ice ball&#39;s edge, ensuring it exceeds the preoperative planned tumor coverage area by 0.5 cm while the temperature probe in the rectal anterior space remains above 0 &#176;C.</li>
	</ol>
	</li>
	<li>Gradually reduce the freezing power while maintaining the ice ball range for 5 min.</li>
	<li>Apply helium gas for rapid warming to reach above 15 &#176;C and maintain for 5 min.</li>
	<li>Repeat the low temperature and rewarming melting cycle.</li>
	<li>Remove all probes, apply pressure to the puncture site to stop bleeding, and secure with a dressing.</li>
	<li>Observe the color of the urinary catheter&#39;s contents. If the urine is clear, bladder irrigation is unnecessary; if blood is visible in the urine, perform bladder irrigation and transfer the patient to the anesthesia recovery room.</li>
	<li>Discharge the patient from the hospital 2-3 days after the removal of the urinary catheter post surgery.</li>
</ol>
6. Evaluation
<ol>
	<li>Oncology evaluation
	<ol>
		<li>Recheck PSA at 1 and 3 months post surgery, then recheck once every 3 months.</li>
		<li>Imaging examination: Recheck 18F-PSMA PET/MRI at 6 months post surgery; T2WI indicates the disappearance of radioactive concentration in the original right peripheral zone.</li>
	</ol>
	</li>
	<li>Functional evaluation (followed by re-examination every month):
	<ol>
		<li>Measure the International Prostate Symptom Score (IPSS), which is currently internationally recognized as the best means to judge the severity of lower urinary tract symptoms (LUTS).</li>
		<li>Measure the Quality-of-life score (Qol score) to understand patients&#39; subjective feelings about the current level of LUTS.</li>
		<li>Measure the maximum urinary flow rate (Qmax) to understand patients&#39; concise objective indicators of current LUTS levels.</li>
		<li>Use the International Consultation on Incontinence Questionnaire-Short Form (ICI-Q-SF) to evaluate whether there is urethral sphincter injury after cryoablation.</li>
		<li>Measure the International Index of erectile function-5 (IIEF-5) to evaluate whether there is neurovascular bundle damage after cryoablation.</li>
	</ol>
	</li>
</ol>

<ol><li>Siegel, R. L., Giaquinto, A. N., Jemal, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cancer+statistics%2C+2024%5BTitle%5D)+AND+%22CA+Cancer+J+Clin%22%5BJournal%5D)">Cancer statistics, 2024.</a> CA Cancer J Clin. 74 (1), 12-49 (2024).</li>
<li>Cornford, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((EAU-EANM-ESTRO-ESUR-ISUP-SIOG+guidelines+on+prostate+cancer-2024+update.+Part+I%3A+Screening%2C+diagnosis%2C+and+local+treatment+with+curative+intent%5BTitle%5D)+AND+%22Eur+Urol%22%5BJournal%5D)">EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent.</a> Eur Urol. 86 (2), 148-163 (2024).</li>
<li>Maljkovic, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Time+trends+for+the+use+of+active+surveillance+and+deferred+treatment+for+localised+prostate+cancer+in+Sweden%3A+a+nationwide+study%5BTitle%5D)+AND+%22Scand+J+Urol%22%5BJournal%5D)">Time trends for the use of active surveillance and deferred treatment for localised prostate cancer in Sweden: a nationwide study.</a> Scand J Urol. 59, 200-206 (2024).</li>
<li>Barqawi, A. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeted+focal+therapy+for+the+management+of+organ-confined+prostate+cancer%5BTitle%5D)+AND+%22J+Urol%22%5BJournal%5D)">Targeted focal therapy for the management of organ-confined prostate cancer.</a> J Urol. 192 (3), 749-753 (2014).</li>
<li>Ahmed, H. U. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+index+lesion+and+the+origin+of+prostate+cancer%5BTitle%5D)+AND+%22N+Engl+J+Med%22%5BJournal%5D)">The index lesion and the origin of prostate cancer.</a> N Engl J Med. 361 (17), 1704-1706 (2009).</li>
<li>Eggener, S. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Focal+therapy+for+localized+prostate+cancer%3A+a+critical+appraisal+of+rationale+and+modalities%5BTitle%5D)+AND+%22J+Urol%22%5BJournal%5D)">Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.</a> J Urol. 178 (6), 2260-2267 (2007).</li>
<li>Sommer, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Focal+ablation+of+prostate+cancer%3A+four+roles+for+magnetic+resonance+imaging+guidance%5BTitle%5D)+AND+%22Can+J+Urol%22%5BJournal%5D)">Focal ablation of prostate cancer: four roles for magnetic resonance imaging guidance.</a> Can J Urol. 20 (2), 6672-6681 (2013).</li>
<li>Durand, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Focal+cryoablation%3A+a+treatment+option+for+unilateral+low-risk+prostate+cancer%5BTitle%5D)+AND+%22BJU+Int%22%5BJournal%5D)">Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.</a> BJU Int. 113 (1), 56-64 (2014).</li>
<li>Haider, M. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Multiparametric+magnetic+resonance+imaging+in+the+diagnosis+of+clinically+significant+prostate+cancer%3A+an+updated+systematic+review%5BTitle%5D)+AND+%22Clin+Oncol+%28R+Coll+Radiol%29%22%5BJournal%5D)">Multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: an updated systematic review.</a> Clin Oncol (R Coll Radiol). 33 (12), e599-e612 (2021).</li>
<li>Eiber, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Prostate-specific+membrane+antigen+ligands+for+imaging+and+therapy%5BTitle%5D)+AND+%22J+Nucl+Med%22%5BJournal%5D)">Prostate-specific membrane antigen ligands for imaging and therapy.</a> J Nucl Med. 58 (Suppl 2), 67S-76S (2017).</li>
<li>Marconi, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Robot-assisted+radical+prostatectomy+after+focal+therapy%3A+oncological%2C+functional+outcomes+and+predictors+of+recurrence%5BTitle%5D)+AND+%22Eur+Urol%22%5BJournal%5D)">Robot-assisted radical prostatectomy after focal therapy: oncological, functional outcomes and predictors of recurrence.</a> Eur Urol. 76 (1), 27-30 (2019).</li>
<li>Bhat, K. R. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Outcomes+of+salvage+robot-assisted+radical+prostatectomy+after+focal+ablation+for+prostate+cancer+in+comparison+to+primary+robot-assisted+radical+prostatectomy%3A+a+matched+analysis%5BTitle%5D)+AND+%22Eur+Urol+Focus%22%5BJournal%5D)">Outcomes of salvage robot-assisted radical prostatectomy after focal ablation for prostate cancer in comparison to primary robot-assisted radical prostatectomy: a matched analysis.</a> Eur Urol Focus. 8 (5), 1192-1197 (2022).</li>
</ol>

The authors have no conflicts of interest to disclose.

Radical prostatectomy and radiotherapy remain the primary treatment modalities for localized prostate cancer2. However, the relatively high incidence of postoperative complications-such as urinary incontinence and erectile dysfunction after surgery, as well as radiation cystitis and radiation proctitis associated with radiotherapy-leads some patients to refuse these treatments. This refusal is often driven by their fear of postoperative complications and higher demands for quality of life. To avoi...

Prostate cancer is the most common malignant tumor among male urinary system diseases, and with the widespread application of prostate-specific antigen (PSA) screening, the proportion of patients diagnosed with localized low-risk prostate cancer has been increasing year by year1. The treatment methods for low-risk prostate cancer patients with a life expectancy greater than 10 years primarily include radical prostatectomy, radiotherapy, active surveillance (AS), and focal therapy2. Radical prostatectomy and radiotherapy remain the primary methods for treating localized prostate cancer in China; however, the high incidence of postoperative complications leads some patients to refuse treatment due to fear and quality-of-life concerns. Although AS can avoid some complications and decline in quality of life associated with local treatments, patients still face the risks of elevated PSA levels and ongoing progression of Gleason scores, resulting in psychological anxiety3.
Currently, there is a lack of suitable treatment options for low-risk prostate cancer patients who refuse radical surgery and are concerned about the risk of progression after AS. Super-AS is a novel treatment involving the application of 18F-PSMA PET/MR multimodal medical imaging, combined with real-time fusion of intraoperative transrectal ultrasound images, thereby enabling precise navigation for targeted argon-helium cryoablation therapy. It combines the patient&#39;s health status and subjective willingness to implement a more proactive clinical approach to localized therapy. Super-AS not only alleviates the potential side effects associated with radical surgery and radiotherapy for patients but also reduces the psychological stress related to concerns about the risk of tumor progression. According to the pathological characteristics of prostate cancer, &#34;Super-AS&#34; can be considered as a treatment option for localized low-risk prostate cancer4. This study provides new ideas and evidence for the establishment of new treatment methods for low-risk prostate cancer by preliminarily exploring the effectiveness and feasibility of this treatment approach.

<table><tbody><tr><td>Endocare Cryotherapy System</td><td>CryoCare Touch</td><td></td><td></td></tr><tr><td>fusion ultrasound</td><td>BK</td><td></td><td></td></tr><tr><td>Levofloxacin</td><td>Beijing Jiluohua Pharmaceutical Co., Ltd</td><td></td><td></td></tr><tr><td>temperature probe</td><td>CryoCare Touch</td><td></td><td></td></tr><tr><td>Variable probe&amp;nbsp;</td><td>CryoCare Touch</td><td></td><td></td></tr></tbody></table>

a new technique for treating low-risk prostate cancer&#8212;super active surveillance

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance

The treatment methods for patients with localized low-risk prostate cancer whose life expectancy is &#62; 10 years mainly include radical prostatectomy, radiotherapy, active surveillance (AS), and focal therapy of low-risk prostate cancer. Research shows that only 3% of patients with low-risk prostate cancer experience disease progression or death, which indicates that there is overtreatment. The number of patients who choose active monitoring is increasing, but in the process of treatment, they often suffer great psychological pressure. Therefore, we are trying to adopt a more active treatment mode than active surveillance-Super Active Surveillance (Super-AS). Super-AS involves the application of 18F-PSMA PET/MR multimodal medical imaging, combined with real-time fusion of intraoperative transrectal ultrasound images, thereby enabling precise navigation for targeted argon-helium cryoablation therapy. The significance of Super-AS lies in its ability to effectively manage tumors in oncology while exerting minimal impact on functionality. Even if the focal therapy fails, the subsequent radical prostatectomy makes no significant difference in the overall oncological control, functional (urinary orifice and sexual function), and postoperative complications. Therefore, precise focal therapy can be an alternative transitional treatment for patients, from active monitoring to radical treatment, and it can also be seen as a &#34;future bridge&#34; for the treatment of localized prostate cancer. Consequently, Super-AS is a potentially promising therapeutic option for patients who meet the indications.

Nine patients underwent surgery successfully, with no intraoperative complications. All 12 lesions were subjected to cryoablation, with a median ablation time of 46 min (ranging from 34 to 65 min). The urinary catheters were successfully removed in all cases 2-3 days postoperatively. The median follow-up time was 37 months (ranging from 14 to 61 months), and the postoperative PSA levels significantly decreased compared to preoperative levels. As of now, the follow-up evaluations for the six patients have shown no oncolog...

Overtreatment is often administered to patients with low-risk prostate cancer; super-active surveillance can help avoid such overtreatment.

The treatment methods for patients with localized low-risk prostate cancer whose life expectancy is &#62; 10 years mainly include radical prostatectomy, ...

I focus on prostate cancer, where many patients with low-risk disease still undergo unnecessary treatment. My goal is to develop a more proactive and patient-centered approach to active surveillance. Currently our imaging technologies are needed to identify latency, enable prices, focal tumor eradication, and achieve the optimal balance between oncological control and functional preservation.Super active surveillance is a safe, effective, and feasible novel treatment street for low-risk prostate cancer. Cryoablation for prostate cancer demonstrates the great potential of the application of cryotherapy and immunotherapy, and the immune effect of cryoablation require more clinical and basics research to explore the specific mechanism. To begin, obtain a patient list that includes patients who have a pathologically-confirmed diagnosis of prostate adenocarcinoma obtained through a prostate system puncture.Ensure the availability of a cryotherapy system and a real-time image fusion ultrasound system. Prepare a USB flash drive containing 18F-PSMA PET/MR imaging data. Next, choose the appropriate puncture target framework according to the prostate volume and tumor location.Prepare a V-shaped variable cryoprobe with an adjustable diameter range from 1.5 to five centimeters and two temperature probes. Now, connect the USB flash drive to the integrated ultrasound system. Import the imaging data into the ultrasound fusion software for preoperative planning and target marking.Complete the full cryoablation preoperative plan. Next, position the patient in the lithotomy position. Administer 0.5 grams of levofloxacin intravenously 30 minutes before surgery.Insert a three-lumen pure silicone catheter following the infusion. Apply ultrasound and preoperative planning markers from the 18F-PSMA PET/MR images to perform intraoperative registration. Now, insert the variable probe into the identified lesion using the image fusion guidance.Place a temperature probe in the perineal puncture site anterior to the rectum or in the Denonvilliers fascia. Irrigate the bladder with saline solution through the three-lumen catheter to protect the urethra from frostbite. To start the cryotherapy system, rapidly lower the front end of the cryoprobe to below minus 140 degrees Celsius.Use ultrasound to monitor the ice ball formation in real time, ensuring its edge extends 0.5 centimeters beyond the preoperative tumor boundary while keeping the rectal temperature probe above zero degrees Celsius. Gradually reduce the freezing power while maintaining the ice ball's coverage area for five minutes. Apply helium gas to rapidly warm the probe tip to above 15 degrees Celsius, and maintain the temperature for five minutes.Once cryotherapy is complete, remove all probes from the patient. Apply pressure to the puncture site to stop bleeding and cover with a sterile dressing. Observe the urine color in the catheter.If the urine is clear, do not perform bladder irrigation. If blood is visible, perform bladder irrigation, then transfer the patient to the anesthesia recovery room. Nine patients underwent surgery successfully without any intraoperative complications.A total of 12 prostate adenocarcinoma lesions were treated using cryoablation across the nine patients. The median postoperative follow-up time was 37 months, with a range of 14 to 61 months.

a-new-technique-for-treating-low-risk-prostate-cancersuper-active

Research

JoVE Journal

Medicine

To demonstrate MR cancer molecular imaging with a small peptide targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma in a mouse prostate cancer model.

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

The goal of this protocol is to demonstrate the intra-prostatic injection of prostate cancer cells, with subsequent castration. Orthotopic pre-clinical models of androgen-dependent and castration-resistant prostate cancer are critical to study the disease in the context of a clinically relevant tumor microenvironment and an immunocompetent host.

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Presented herein is a protocol to perform targeted biopsy of the prostate using an MRI-ultrasound fusion system.

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

This article presents and describes an outpatient treatment for prostate cancer using focal laser ablation. Laser catheter placement is guided by MRI-ultrasound fusion imaging in a fashion similar to prostate needle biopsy. Treatment is monitored in real-time with a thermal probe, placed adjacent to the laser fiber.<br...

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Robot-assisted Retzius-sparing radical prostatectomy is a technique that enables to preserve urinary continence or facilitates recovery of urinary continence in the majority of patients. Patients must be informed about the risk of a positive surgical margin.

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Prostate biopsy is the gold standard diagnostic method for prostate cancer. Cognitive fusion-guided prostate biopsy, which combines transrectal ultrasound with pre-measured MRI parameters, improves biopsy accuracy and enhances the detection rate of clinically significant prostate cancer.

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

This study presents an enhanced transperineal prostate biopsy technique using a cone-shaped double-hole method and dual-plane probe guidance. These modifications reduce trauma, enhance patient recovery, and improve biopsy accuracy, making the procedure a reliable and minimally invasive approach for prostate cancer diagnosis.

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Here, we present a standardized protocol for detecting prostate cancer using stimulated Raman histology (SRH) on biopsy samples due to advantages over traditional histopathology, focusing on sample preparation, imaging, and artificial intelligence to improve the cancer-to-tissue ratio. Additionally, it supports biobanking for transcriptomics, organoid or xenograft models, and identification of intraoperative surgical margins.

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

A new species of cellular prion protein (PrPC) has recently been identified in uninfected human brains using the methods described here. These methods can be used to isolate various PrP species, while some of them are also useful in isolating other misfolded protein aggregates from human brains.

Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain

We present a simple agarose overlay platform to grow 3D multicellular spheroids using neuroendocrine cancer cell lines. This method provides a very convenient way to examine the effect of therapeutic drugs on the neuroendocrine tumor cells. It could also help us establish human neuroendocrine tumor spheroids for cancer therapy.

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Learn super-active surveillance for low-risk prostate cancer using cryoablation and advanced imaging technologies. This method reduces overtreatment while preserving patient quality of life and functional outcomes.

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Explore More Videos